Cyramza (Ramucirumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The cyramza (ramucirumab) market research report is one of a series of new reports that provides Cyramza (Ramucirumab) market statistics, including the Cyramza (Ramucirumab) industry's global market size, regional shares, competitors with a Cyramza (Ramucirumab) market share, detailed Cyramza (Ramucirumab) market segments, market trends and opportunities, and any further data you may need to thrive in the Cyramza (Ramucirumab) industry. This Cyramza (Ramucirumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cyramza (ramucirumab) market size is expected to see strong growth in the next few years. It will grow to $1,686.3 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing clinical trials, increasing cancer screening programs, demand for treatment, growing number of patients, and changing li. Major trends in the forecast period include expanding application of ramucirumab, FDA approvals, emphasis on personalized medicine, growing adoption of combination medicines, and product innovation.

The increasing incidence of cancer is expected to drive the growth of the cyramza (ramucirumab) market in the coming years. Cancer is a group of diseases marked by uncontrolled cell growth and the spread of cells to other body parts. The rise in cancer cases is due to factors like an aging population, lifestyle choices, environmental exposures, improved detection, and genetic factors. Cyramza (ramucirumab) is used in cancer treatment to target and inhibit the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent the growth of blood vessels that nourish tumors and slow cancer progression. For example, according to a report by the Australian Institute of Health and Welfare published in August 2024, Australia is projected to have around 209,000 new cancer diagnoses by 2034, up from an estimated 169,000 in 2024. This increase reflects both the growing population and rising cancer rates. Furthermore, cancer is expected to account for approximately 30% of all deaths in the country by 2024. As a result, the growing incidence of cancer is driving the expansion of the cyramza (ramucirumab) market.

A key trend in the cyramza (ramucirumab) market is the development of innovative drug therapies aimed at improving treatment for patients with advanced or metastatic cancer. Drugs like ramucirumab for hepatocellular carcinoma (HCC) target specific cancer markers to slow tumor growth and improve survival rates. For instance, in October 2022, Innovent Biologics Inc., a Chinese biopharmaceutical company, announced that China's National Medical Products Administration (NMPA) approved the supplemental New Drug Application (sNDA) for Cyramza (ramucirumab) in treating patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein level of ≥400 ng/mL and have already received sorafenib. Additionally, Cyramza was approved in combination with paclitaxel as a second-line treatment for advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, becoming the first and only targeted drug approved for this indication in China.

In March 2022, Innovent Biologics Inc. partnered with Eli Lilly and Company to develop and commercialize cutting-edge cancer therapies in China. This partnership aims to combine the strengths of both companies to advance innovative cancer treatments, starting with the monoclonal antibody Cyramza (ramucirumab), and enhance cancer treatment by targeting tumor growth through angiogenesis inhibition. Eli Lilly and Company, a US-based pharmaceutical company, manufactures Cyramza (ramucirumab).

The key player operating in the cyramza (ramucirumab) market is Eli Lilly and Company.

North America was the largest region in the cyramza (ramucirumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cyramza (ramucirumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cyramza (ramucirumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cyramza (ramucirumab) is a monoclonal antibody used in cancer treatment. It works by targeting and inhibiting the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent tumor blood vessel formation. Cyramza is commonly used to treat various cancers, including gastric, colorectal, and lung cancer.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of cyramza (ramucirumab) are 100mg/Box and 500mg/Box. The 100mg/Box refers to the packaging size of Cyramza, with each box containing 100 mg of the drug. This smaller packaging is typically used for patients requiring a lower dose of the medication, facilitating easier distribution and use in different medical settings. Cyramza has various applications in the treatment of advanced gastric cancer, GEJ adenocarcinoma, non-small cell lung carcinoma, metastatic colorectal cancer (MCRC), and hepatocellular carcinoma (HCC). It is utilized by end users such as hospitals, cancer treatment centers, ambulatory surgical centers, and research institutes.

The cyramza (ramucirumab) market consists of sales of cyramza (ramucirumab) iv infusion and combination therapy formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.